Karmustin Teva (Carmustine)

Carmustine belongs to the nitrosourea class of alkylating agents. It forms covalent bonds with DNA and RNA, creating cross‑links that prevent replication and transcription. This damage triggers programmed cell death (apoptosis) in rapidly dividing cancer cells, thereby slowing tumor growth.

The specific dose of Karmustin is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal and hepatic function, and treatment protocol. Dosing regimens are individualized and should not be altered without medical guidance.

Carmustine is classified as potentially harmful to a developing fetus and may be excreted in breast milk. It is generally contraindicated during pregnancy and breastfeeding unless the potential benefit outweighs the risk, as assessed by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Karmustin (Carmustine) is a nitrosourea alkylating agent, whereas alternatives such as temozolomide belong to the alkylating imidazotetrazine class. Carmustine is often used when a more aggressive cross‑linking mechanism is desired, but it may have a higher risk of pulmonary toxicity compared with some oral agents.

Karmustin should be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken, as temperature excursions can compromise stability and potency.

Karmustin is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel in a clinical setting, following aseptic technique and the dosing schedule prescribed by the treating oncologist.

The most serious risks include severe bone marrow suppression leading to pancytopenia, pulmonary toxicity such as interstitial pneumonitis, and the rare possibility of secondary malignancies. Patients should be monitored closely for signs of infection, respiratory distress, and abnormal blood counts.

Karmustin is contraindicated in patients with known hypersensitivity to Carmustine or other nitrosoureas, those with severe bone marrow failure, uncontrolled infections, or significant pulmonary disease. It should also be avoided in pregnant women unless absolutely necessary.